Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (Q29615030)

From Wikidata

Jump to navigation Jump to search

scientific article (publication date: August 2002)

Language	Label	Description	Also known as
English	Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia	scientific article (publication date: August 2002)

Statements

scholarly article

0 references

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia (English)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Shah NP

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Nicoll JM

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Nagar B

3

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Gorre ME

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Paquette RL

5

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Kuriyan J

6

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

Sawyers CL

7

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

language of work or name

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

publication date

August 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

117-25

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12204532

30 April 2017

An activating mutation in the ATP binding site of the ABL kinase domain.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

SETOR: hardware-lighted three-dimensional solid model representations of macromolecules

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Alpha1-acid glycoprotein expressed in the plasma of chronic myeloid leukemia patients does not mediate significant in vitro resistance to STI571.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Functional interaction between DNA-PK and c-Abl in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Increase in mutant frequencies in mice expressing the BCR-ABL activated tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Interaction between ATM protein and c-Abl in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Structural basis for activation of human lymphocyte kinase Lck upon tyrosine phosphorylation

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

c-Abl tyrosine kinase regulates the human Rad9 checkpoint protein in response to DNA damage

1 reference

https://api.crossref.org/works/10.1016%2FS1535-6108%2802%2900096-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q29615030&oldid=1694203590"